SCHEMBL19639458

SCHEMBL19639458

CCOCOc1ccccc1C1(C)CCCCC1.OBO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR Q13258 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
HCN1 O60741 4/20 0.33
HCN4 Q9Y3Q4 4/20 0.33
CYP2C19 P33261 1/20 0.32
ALDH1A1 P00352 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CETP P11597 1/20 0.31
PDK2 Q15119 1/20 0.31
HDAC4 P56524 1/20 0.31
HCN3 Q9P1Z3 1/20 0.31
HCN2 Q9UL51 1/20 0.31
THRB P10828 1/20 0.31
SLC6A2 P23975 2/20 0.30
SLC6A3 Q01959 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23927772 0.94 PTGDR (0.39) PTGDRPTGDR2LMNAGAAKMT2A
SCHEMBL17847413 0.76 PTGDR (0.44) PTGDRPTGDR2LMNAKMT2AALDH1A1
SCHEMBL8681745 0.76 PTGDR (0.43) PTGDRPTGDR2LMNAKMT2AALDH1A1
SCHEMBL19639459 0.75 PTGDR (0.44) PTGDRPTGDR2
SCHEMBL22871193 0.74 ALDH1A1 (0.47) LMNAGAAKMT2ACYP2C19ALDH1A1
SCHEMBL17847398 0.74 PTGDR2 (0.43) PTGDRPTGDR2CETPSLC6A4
SCHEMBL17847388 0.72 PTGDR (0.41) PTGDRPTGDR2ALDH1A1
SCHEMBL11919524 0.71 SIGMAR1 (0.49) LMNAKMT2AALDH1A1NPSR1HPGD
SCHEMBL17847410 0.70 LMNA (0.31) PTGDRPTGDR2LMNAGAAKMT2A
SCHEMBL8751778 0.70 L3MBTL1 (0.47) LMNAGAACYP2C19ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233806-B1 HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS GALDERMA RES & DEV (FR) 2021-10-27 EP disclosed
US-10647688-B2 Compounds, synthesis method thereof and use of same in medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-05-12 US disclosed
US-20170342040-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342040-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS RARA, RARB, RARG PTGDR 365/4885PTGDR2 225/4885LMNA 4037/4885
US-10647688-B2 Compounds, synthesis method thereof and use of same in medicine and in cosmetics RARA, RARB, RARG PTGDR 300/4885PTGDR2 224/4885LMNA 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.